Notice of Annual General Meeting of Vitrolife AB (publ)

The Annual General Meeting of Vitrolife AB (publ) will take place on Thursday May 2, 2019, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Thursday, April 25, 2019.

Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83 or by e-mail investors@vitrolife.com. Full name/business name, preferably personal identification number/ company registration number (or the equivalent), address, telephone number, number of shares, details of any advisors and where appropriate details of a representative or proxy must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.vitrolife.com.

Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting. Such registration must be carried out no later than Thursday, April 25, 2019.

The following proposals will be amongst those presented at the Annual General Meeting:

• Dividend of SEK 0.85 per share and Monday, May 6, 2019, as the record date for the dividend.

• The Election Committee proposes that the Board shall consist of five members. The Election Committee proposes re-election of the Board members Barbro Fridén, Lars Holmqvist, Pia Marions and Jón Sigurdsson and election of the new Board member Henrik Blomquist. Carsten Browall has declined re-election. It is proposed that Jón Sigurdsson is elected as new Chairman of the Board. Remuneration to the Board members is proposed to be SEK 2,165,000, of which SEK 825,000 to the Chairman of the Board, SEK 275,000 to each of the other members of the Board. SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee and SEK 30,000 to the other members of these committees. The proposal equals a decrease of SEK 75,000 of the total amount compared to the previous year. 

• Authorization for the Board to resolve to issue new shares up until the next Annual General Meeting.

• Authorization for the Board to resolve on acquisition of the company’s own shares during the period up until the next Annual General Meeting.

Attachment: Full notice

Gothenburg, March 26, 2019
VITROLIFE AB (publ)
The Board

Contact:

Carsten Browall, Chairman of the Board, phone 46 (0)70 255 65 32
Mikael Engblom, CFO, phone 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on March 26, 2019. 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 390 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags: